300142 Stock Overview
Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Walvax Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.26 |
| 52 Week High | CN¥34.35 |
| 52 Week Low | CN¥13.65 |
| Beta | 0.69 |
| 1 Month Change | -19.98% |
| 3 Month Change | -27.58% |
| 1 Year Change | -57.29% |
| 3 Year Change | -74.53% |
| 5 Year Change | -47.61% |
| Change since IPO | 46.84% |
Recent News & Updates
There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings
Apr 07
Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 02Shareholder Returns
| 300142 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -2.9% | -2.6% | -0.4% |
| 1Y | -57.3% | -26.4% | -17.6% |
Return vs Industry: 300142 underperformed the CN Biotechs industry which returned -26.9% over the past year.
Return vs Market: 300142 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 300142 volatility | |
|---|---|
| 300142 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300142's share price has been volatile over the past 3 months.
Volatility Over Time: 300142's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,388 | n/a | www.walvax.com |
Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age.
Walvax Biotechnology Co., Ltd. Fundamentals Summary
| 300142 fundamental statistics | |
|---|---|
| Market cap | CN¥22.81b |
| Earnings (TTM) | CN¥419.39m |
| Revenue (TTM) | CN¥4.11b |
54.4x
P/E Ratio5.5x
P/S RatioIs 300142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300142 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.11b |
| Cost of Revenue | CN¥750.76m |
| Gross Profit | CN¥3.36b |
| Other Expenses | CN¥2.94b |
| Earnings | CN¥419.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 81.75% |
| Net Profit Margin | 10.19% |
| Debt/Equity Ratio | 6.7% |
How did 300142 perform over the long term?
See historical performance and comparison